Compare Kaltura Inc (KLTR) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kaltura Inc vs Mesoblast Limited — how do they compare? Kaltura Inc trades at $1.32 (market cap $199.08M), while Mesoblast Limited trades at $14.24 (market cap $1.75B). The key difference: Mesoblast Limited is far larger — about 8.8× Kaltura Inc's market cap, and Kaltura Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kaltura Inc for 21 Days and Mesoblast Limited for 15 Days on average.
| KLTR | MESO | |
|---|---|---|
Market Cap | $199.08M | $1.75B |
Volume | 175,927 | 239,027 |
Sector | Technology | Health |
52-Week High | $1.89 | $20.96 |
52-Week Low | $1.08 | $13.19 |
Typical Hold Time | 21 Days | 15 Days |
Enterprise Value | $211.29M | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLTR trades at $1.32, down 0.75% on the day, with bearish technical signals from moving averages. The company shows improving fundamentals with revenue stabilizing around $181M and narrowing losses, though it remains unprofitable with negative ROE. Recent analyst coverage leans positive with 44% buy ratings, supported by multiple industry awards and AI platform deployments in 2026.
The outlook remains speculative given persistent losses and high valuation ratios, but growing AI integration and award recognition provide catalysts. Key risks include cash burn, competitive pressure, and execution challenges in achieving profitability. Wall Street sentiment is cautiously optimistic despite technical weakness.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
